Home  »  Company   »  We Just Learned Something New! After InVivo Therap...

We Just Learned Something New! After InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV)’s 16.01% Gain This Week

During the recent session, InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV)’s traded shares were 17.94 million, with the beta value of the company hitting 1.30. At the last check today, the stock’s price was $11.99, reflecting an intraday gain of 171.31% or $7.57. The 52-week high for the NVIV share is $20.23, that puts it down -68.72 from that peak though still a striking 70.81% gain since the share price plummeted to a 52-week low of $3.50. The company’s market capitalization is $5.79M, and the average intraday trading volume over the past 10 days was 20620.0 shares, and the average trade volume was 12.74K shares over the past three months.

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) trade information

InVivo Therapeutics Holdings Corp. (NVIV) registered a 171.31% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 171.31% in intraday trading to $11.99 this Wednesday, 08/03/22, hitting a weekly high. The stock’s 5-day price performance is 16.01%, and it has moved by 14.51% in 30 days. Based on these gigs, the overall price performance for the year is -71.76%. The short interest in InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) is 56870.0 shares and it means that shorts have 5.85 day(s) to cover.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


The consensus price target of analysts on Wall Street is $937.50, which implies an increase of 98.72% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $937.50 and $937.50 respectively. As a result, NVIV is trading at a discount of -7719.02% off the target high and -7719.02% off the low.

While earnings are projected to return 77.20% in 2022.

NVIV Dividends

InVivo Therapeutics Holdings Corp. is due to release its next quarterly earnings between August 11 and August 17. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV)’s Major holders

InVivo Therapeutics Holdings Corp. insiders own 0.10% of total outstanding shares while institutional holders control 11.50%, with the float percentage being 11.52%. Blackrock Inc. is the largest shareholder of the company, while 20 institutions own stock in it. As of Mar 30, 2022, the company held over 34713.0 shares (or 2.50% of all shares), a total value of $0.3 million in shares.

The next largest institutional holding, with 11704.0 shares, is of Vanguard Group, Inc. (The)’s that is approximately 0.84% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $0.1 million.

Also, the Mutual Funds coming in first place with the largest holdings of InVivo Therapeutics Holdings Corp. (NVIV) shares are Vanguard Total Stock Market Index Fund and Fidelity Extended Market Index Fund. Data provided on Mar 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 10346.0 shares. This amounts to just over 0.74 percent of the company’s overall shares, with a $89234.0 market value. The same data shows that the other fund manager holds slightly less at 6864.0, or about 0.49% of the stock, which is worth about $36516.0.

Leave a Comment

Your email address will not be published.

On Key

Related Posts